J&J Begins Trial of Tip-Based Javelin IVL Catheter for Hard-to-Treat Arteries

Johnson & Johnson has launched a pivotal study of its Javelin intravascular lithotripsy (IVL) catheter, designed by Shockwave Medical to treat “difficult-to-cross” coronary arteries. Unlike balloon-based devices, Javelin emits sound pressure waves from its tip, allowing it to break up calcium deposits without needing to cross the blockage first—a key advantage in severely narrowed vessels.

The study will enroll up to 158 patients across 35 U.S. and U.K. sites to support coronary use approval. Javelin was previously cleared for peripheral vessels, expanding Shockwave’s reach in the IVL space.

J&J’s $13.1 billion acquisition of Shockwave and investment in balloon-free technology positions it against balloon-based rivals like Abbott and Boston Scientific. While Javelin targets only about 5% of the IVL market, it addresses a critical unmet need in complex coronary procedures.

23-04-2025